Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07367100

A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke

The purpose of this study is to assess the safety and the effectiveness of the Adaptive Tip Catheter (ATC) used as a first line direct aspiration thrombectomy technique for patients suffering of an acute ischemic stroke.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ischemic Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Stroke Vascular Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UZ Antwerpen, Edegem, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age greater than or equal to (>=) 18 years, less than or equal to (<=) 90 years, at the time of consent
  • Signs and symptoms consistent with the diagnosis of acute ischemic stroke in the anterior circulation that can be treated with endovascular thrombectomy approaches
  • Endovascular treatment can be initiated (defined as access puncture) within 24 hours from time last known well
  • Baseline National Institutes of Health Stroke Scale (NIHSS) score >= 6
  • Baseline Alberta Stroke Program Early CT Score (ASPECTS) >= 3
  • A signed and dated Informed Consent Form (ICF) or Investigator Statement for emergency procedure (as allowed according to country regulations and approved by EC) has been obtained

Exclusion criteria

  • Known pregnancy, as evidenced by positive pregnancy test for women of childbearing potential or breast feeding
  • Life expectancy less than (<) 90 days prior to stroke onset
  • Known hemorrhagic diathesis disorder, coagulation factor deficiency or oral anticoagulant therapy with known International Normalized Ratio (INR) greater than (>) 3.0
  • Clinical symptoms and/or CT/MRI evidence suggestive of bilateral stroke or stroke in multiple vascular territories, defined as occlusions in more than one vessel not downstream from each other (for example, bilateral anterior circulation, anterior/posterior circulation)
  • Clinical history, past imaging or clinical judgement suggest that the intracranial occlusion is chronic
  • Computed Tomography/ Magnetic Resonance Imaging (CT/MRI) evidence of recent/fresh hemorrhage
  • Baseline CT or MRI showing mass effect
  • Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Patients in observational, natural history, and/or epidemiological studies not involving intervention are eligible
  • Cerebral catheter angiographic evidence of pre-existing arterial disease, that potentially impacts treatment and/or outcome (for example, vasculitis)
  • Any occlusion or stenosis that limits device access to the target area (for example, carotid dissection, tandem occlusions) or requiring acute stenting to achieve access
  • Cerebral catheter angiographic evidence of multiple cerebrovascular occlusions, defined as occlusions in more than one vessel not downstream from each other (for example, bilateral anterior circulation, anterior/posterior circulation)
  • Excessive vascular access tortuosity that will likely prevent endovascular access with the adaptive tip catheter (ATC)
  • Baseline expanded thrombolysis in cerebral infarction (eTICI) > 1

Treatment and study plan

Adaptive Tip Catheter

Procedure

Patients will undergo mechanical thrombectomy using ATC.

Primary outcomes

  1. Third Pass Reperfusion Assessed by Independent Imaging Core Lab

    Time frame: Intraoperative

    Successful achievement of the third pass reperfusion is defined as achieving an Expanded Thrombolysis in Cerebral Infarction (eTICI) score of 2b50 or greater using no more than three passes with the study device in the target vessel, and without any rescue therapy.

Secondary outcomes

  1. First Pass Reperfusion

    Time frame: Intraoperative

    Successful achievement of the first pass reperfusion is defined as achieving an eTICI score of 2c or greater, as determined by the independent imaging core lab, with one pass of the study device in the target vessel, and without any rescue therapy.

  2. Final Procedural Reperfusion

    Time frame: Intraoperative

    Successful achievement of the final procedural reperfusion is defined as achieving a final (end of procedure) eTICI score of 2b50 or greater in the target vessel as determined by the independent imaging core lab.

  3. Modified Rankin Scale (mRS) Score of 0-2 at 90 days Post-Procedure

    Time frame: At 90 days post-procedure

    Percentage of patients with mRS score of 0-2 at 90 days or no change from baseline if pre-ictal mRS greater than (>) 2 will be reported.

  4. Vessel Damage

    Time frame: At 90 days post-procedure

    Number of patients with perforation or dissection in the blood vessel known to be related to or possibly related to the study device will be reported.

  5. All-Cause Mortality

    Time frame: At 90 days post-procedure

    All mortality regardless of causes at 90 days post-procedure will be reported.

  6. Symptomatic Intracranial Hemorrhage (sICH) at 24 hours

    Time frame: At 24 hours after intervention

    sICH is defined as a new intracranial hemorrhage as detected by brain imaging, measured 24 hours after intervention associated with any of the following: greater than or equal to (>=) 4 points total National Institutes of Health Stroke Scale (NIHSS) at the time of diagnosis compared to immediately before worsening; >= 2 point in one NIHSS category; leading to intubation/hemicraniectomy/external ventricular drain (EVD) placement or other major medical/surgical intervention or absence of alternative explanation for deterioration.

Study contacts

Contact information is provided by the study sponsor or research team.

Adriana Popovici

CONTACT

[email protected]

+41 76 396 34 66

Arnaud Nicolas, PhD

CONTACT

[email protected]

+41 79 517 97 36

Sponsors and collaborators

Lead sponsor

Neuravi Limited

Industry

Registry information

Official study title

A Prospective, First in Human Pivotal Study to Evaluate the Adaptive Tip Catheter Used to Treat Acute Ischemic Stroke Patients During Mechanical Thrombectomy

Acronym: PHAST

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 26, 2026
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.